In HF, antialdosterones or mineralocorticoid receptor blockers reduced SCD (subgroup analysis: 5 RCTs), all-cause mortality (subgroup analysis: 10 RCTs) and cardiovascular, all-cause and cardiovascular hospitalisation. Adverse effects (hyperkalaemia, degradation of renal function and gynaecomastia) were, however, significantly higher in the treated group compared with placebo. This evidence concerns the gene NR3C2 and Hyperkalemia.